SELLAS Life Sciences Group (NASDAQ:SLS) Rating Increased to Moderate Buy at Royal Bank of Canada

Royal Bank of Canada upgraded shares of SELLAS Life Sciences Group (NASDAQ:SLS) to a moderate buy rating in a research report sent to investors on Monday morning, Zacks.com reports.

SELLAS Life Sciences Group Price Performance

NASDAQ SLS opened at $1.14 on Monday. SELLAS Life Sciences Group has a 1 year low of $0.50 and a 1 year high of $1.91. The firm has a market cap of $65.85 million, a price-to-earnings ratio of -1.04 and a beta of 2.11. The company has a fifty day moving average price of $1.36 and a 200-day moving average price of $1.10.

SELLAS Life Sciences Group (NASDAQ:SLS) last posted its quarterly earnings results on Tuesday, May 14th. The company reported ($0.21) earnings per share for the quarter. On average, research analysts anticipate that SELLAS Life Sciences Group will post -0.75 EPS for the current fiscal year.

Hedge Funds Weigh In On SELLAS Life Sciences Group

Large investors have recently modified their holdings of the business. Opus Capital Group LLC boosted its position in shares of SELLAS Life Sciences Group by 291.3% in the fourth quarter. Opus Capital Group LLC now owns 135,000 shares of the company’s stock valued at $143,000 after acquiring an additional 100,500 shares during the period. Armistice Capital LLC bought a new stake in SELLAS Life Sciences Group during the fourth quarter valued at approximately $869,000. Finally, Anson Funds Management LP bought a new stake in SELLAS Life Sciences Group during the first quarter valued at approximately $4,881,000. Hedge funds and other institutional investors own 17.38% of the company’s stock.

About SELLAS Life Sciences Group

SELLAS Life Sciences Group, Inc, a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.